Publication

• 1. Lee, S, M Yang, J Kim, S Kang, J Kim, JC Kim, C Jung, T Shin, SH Kim, and C Moon. Trimethyltin-induced hippocampal neurodegeneration: A mechanism-based review. Brain Research Bulletin, 125:187-199 (2016).
• 2. Cho, YS, DM Hung, SY Kwon, C Moon, K Kim, K Lee, SJ Lee, S Hemmi, YE Joo, MS Kim, and C Jung. Efficacy of CD46-targeting chimeric Ad5/35 adenoviral gene therapy for colorectal cancers. Oncotarget, 7(25):38210-38223 (2016).
• 3. Kim, YR, TW Kang, PK To, Xuan Nguyen NT, YS Cho, C Jung, and MS Kim. HOXB13-mediated suppression of p21waf1/cip1 regulates JNK/c-jun signaling in propstate cancer cells. Oncology Reports, 35:2011-2016 (2016).
• 4. Song, S, A Kim, M Brown, C Jung, S Ko, and B Ziaie. An implantable wireless interstitial pressure sensor with integrated guyton chamber. IEEE Trans Biomed Eng, in press (2016).
• 5. Kim, YR, IJ Kim, TW Kang, C Choi, KK Kim, MS Kim, KI Nam, and C Jung. HOXB13 downregulates intracellular zinc and increases NF-kB signaling to promote prostate cancer metastasis. Oncogene, 33:4558-4567 (2014).
• 6. Lee, SY, CH Song, YB Xie, C Jung, HS Choi, and K Lee. SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells. Cancer Letters, 354:390-397 (2014).
• 7. Kim, IJ, TW Kang, T Jeong, Y-R Kim, and C Jung. HOXB13 regulates the prostate-derived Ets factor: Implications for prostate cancer cell invasion. Int J Oncol, 45:869-876 (2014).
• 8. Jung, C, Y Park, Y-R Kim, SB Ryu, and TW Kang. Five-alpha reductase inhibitor influences expression of androgen receptor and HOXB13 in human hyperplastic prostate cancer. Int Braz J Urol, 39:875-883 (2013).